Consensus nomenclature for CD8+ T cell phenotypes in cancer

Lionel Apetoh; Mark J. Smyth; Charles G. Drake; Jean Pierre Abastado; Ron N. Apte; Maha Ayyoub; Jean Yves Blay; Marc Bonneville; Lisa H. Butterfield; Anne Caignard; Chiara Castelli; Federica Cavallo; Esteban Celis; Lieping Chen; Mario P. Colombo; Begoña Comin-Anduix; Georges Coukos; Madhav V. Dhodapkar; Glenn Dranoff; Ian H. Frazer; Wolf Hervé Fridman; Dmitry I. Gabrilovich; Eli Gilboa; Sacha Gnjatic; Dirk Jäger; Pawel Kalinski; Howard L. Kaufman; Rolf Kiessling; John Kirkwood; Alexander Knuth; Roland Liblau; Michael T. Lotze; Enrico Lugli; Francesco Marincola; Ignacio Melero; Cornelis J. Melief; Thorsten R. Mempel; Elizabeth A. Mittendorf; Kunle Odun; Willem W. Overwijk; Anna Karolina Palucka; Giorgio Parmiani; Antoni Ribas; Pedro Romero; Robert D. Schreiber; Gerold Schuler; Pramod K. Srivastava; Eric Tartour; Danila Valmori; Sjoerd H. van der Burg; Pierre van der Bruggen; Benoît J. van den Eynde; Ena Wang; Weiping Zou; Theresa L. Whiteside; Daniel E. Speiser; Drew M. Pardoll; Nicholas P. Restifo; Ana C. Anderson

doi:10.1080/2162402X.2014.998538

Consensus nomenclature for CD8⁺ T cell phenotypes in cancer

Lionel Apetoh, Mark J. Smyth, Charles G. Drake, Jean Pierre Abastado, Ron N. Apte, Maha Ayyoub, Jean Yves Blay, Marc Bonneville, Lisa H. Butterfield, Anne Caignard, Chiara Castelli, Federica Cavallo, Esteban Celis, Lieping Chen, Mario P. Colombo, Begoña Comin-Anduix, Georges Coukos, Madhav V. Dhodapkar, Glenn Dranoff, Ian H. FrazerWolf Hervé Fridman, Dmitry I. Gabrilovich, Eli Gilboa, Sacha Gnjatic, Dirk Jäger, Pawel Kalinski, Howard L. Kaufman, Rolf Kiessling, John Kirkwood, Alexander Knuth, Roland Liblau, Michael T. Lotze, Enrico Lugli, Francesco Marincola, Ignacio Melero, Cornelis J. Melief, Thorsten R. Mempel, Elizabeth A. Mittendorf, Kunle Odun, Willem W. Overwijk, Anna Karolina Palucka, Giorgio Parmiani, Antoni Ribas, Pedro Romero, Robert D. Schreiber, Gerold Schuler, Pramod K. Srivastava, Eric Tartour, Danila Valmori, Sjoerd H. van der Burg, Pierre van der Bruggen, Benoît J. van den Eynde, Ena Wang, Weiping Zou, Theresa L. Whiteside, Daniel E. Speiser, Drew M. Pardoll, Nicholas P. Restifo, Ana C. Anderson

Oncology Research

Research output: Contribution to journal › Article › peer-review

114 Scopus citations

Abstract

Whereas preclinical investigations and clinical studies have established that CD8⁺ T cells can profoundly affect cancer progression, the underlying mechanisms are still elusive. Challenging the prevalent view that the beneficial effect of CD8⁺ T cells in cancer is solely attributable to their cytotoxic activity, several reports have indicated that the ability of CD8⁺T cells to promote tumor regression is dependent on their cytokine secretion profile and their ability to self-renew. Evidence has also shown that the tumor microenvironment can disarm CD8⁺ T cell immunity, leading to the emergence of dysfunctional CD8⁺ T cells. The existence of different types of CD8⁺ T cells in cancer calls for a more precise definition of the CD8⁺ T cell immune phenotypes in cancer and the abandonment of the generic terms “pro-tumor” and “antitumor.” Based on recent studies investigating the functions of CD8⁺ T cells in cancer, we here propose some guidelines to precisely define the functional states of CD8⁺T cells in cancer.

Original language	English (US)
Journal	OncoImmunology
Volume	4
Issue number	4
DOIs	https://doi.org/10.1080/2162402X.2014.998538
State	Published - 2015

Keywords

Anergy
Anticancer immunity
CD8 T cells
Cytotoxicity
Effector
Exhaustion
IFNγ
Senescence
Stemness

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/2162402X.2014.998538

Cite this

Apetoh, L., Smyth, M. J., Drake, C. G., Abastado, J. P., Apte, R. N., Ayyoub, M., Blay, J. Y., Bonneville, M., Butterfield, L. H., Caignard, A., Castelli, C., Cavallo, F., Celis, E., Chen, L., Colombo, M. P., Comin-Anduix, B., Coukos, G., Dhodapkar, M. V., Dranoff, G., ... Anderson, A. C. (2015). Consensus nomenclature for CD8⁺ T cell phenotypes in cancer. OncoImmunology, 4(4). https://doi.org/10.1080/2162402X.2014.998538

Apetoh, L, Smyth, MJ, Drake, CG, Abastado, JP, Apte, RN, Ayyoub, M, Blay, JY, Bonneville, M, Butterfield, LH, Caignard, A, Castelli, C, Cavallo, F, Celis, E, Chen, L, Colombo, MP, Comin-Anduix, B, Coukos, G, Dhodapkar, MV, Dranoff, G, Frazer, IH, Fridman, WH, Gabrilovich, DI, Gilboa, E, Gnjatic, S, Jäger, D, Kalinski, P, Kaufman, HL, Kiessling, R, Kirkwood, J, Knuth, A, Liblau, R, Lotze, MT, Lugli, E, Marincola, F, Melero, I, Melief, CJ, Mempel, TR, Mittendorf, EA, Odun, K, Overwijk, WW, Palucka, AK, Parmiani, G, Ribas, A, Romero, P, Schreiber, RD, Schuler, G, Srivastava, PK, Tartour, E, Valmori, D, van der Burg, SH, van der Bruggen, P, van den Eynde, BJ, Wang, E, Zou, W, Whiteside, TL, Speiser, DE, Pardoll, DM, Restifo, NP & Anderson, AC 2015, 'Consensus nomenclature for CD8⁺ T cell phenotypes in cancer', OncoImmunology, vol. 4, no. 4. https://doi.org/10.1080/2162402X.2014.998538

@article{9a53383ec0034d3388a1a6b7426f73a9,

title = "Consensus nomenclature for CD8+ T cell phenotypes in cancer",

abstract = "Whereas preclinical investigations and clinical studies have established that CD8+ T cells can profoundly affect cancer progression, the underlying mechanisms are still elusive. Challenging the prevalent view that the beneficial effect of CD8+ T cells in cancer is solely attributable to their cytotoxic activity, several reports have indicated that the ability of CD8+T cells to promote tumor regression is dependent on their cytokine secretion profile and their ability to self-renew. Evidence has also shown that the tumor microenvironment can disarm CD8+ T cell immunity, leading to the emergence of dysfunctional CD8+ T cells. The existence of different types of CD8+ T cells in cancer calls for a more precise definition of the CD8+ T cell immune phenotypes in cancer and the abandonment of the generic terms “pro-tumor” and “antitumor.” Based on recent studies investigating the functions of CD8+ T cells in cancer, we here propose some guidelines to precisely define the functional states of CD8+T cells in cancer.",

keywords = "Anergy, Anticancer immunity, CD8 T cells, Cytotoxicity, Effector, Exhaustion, IFNγ, Senescence, Stemness",

author = "Lionel Apetoh and Smyth, {Mark J.} and Drake, {Charles G.} and Abastado, {Jean Pierre} and Apte, {Ron N.} and Maha Ayyoub and Blay, {Jean Yves} and Marc Bonneville and Butterfield, {Lisa H.} and Anne Caignard and Chiara Castelli and Federica Cavallo and Esteban Celis and Lieping Chen and Colombo, {Mario P.} and Bego{\~n}a Comin-Anduix and Georges Coukos and Dhodapkar, {Madhav V.} and Glenn Dranoff and Frazer, {Ian H.} and Fridman, {Wolf Herv{\'e}} and Gabrilovich, {Dmitry I.} and Eli Gilboa and Sacha Gnjatic and Dirk J{\"a}ger and Pawel Kalinski and Kaufman, {Howard L.} and Rolf Kiessling and John Kirkwood and Alexander Knuth and Roland Liblau and Lotze, {Michael T.} and Enrico Lugli and Francesco Marincola and Ignacio Melero and Melief, {Cornelis J.} and Mempel, {Thorsten R.} and Mittendorf, {Elizabeth A.} and Kunle Odun and Overwijk, {Willem W.} and Palucka, {Anna Karolina} and Giorgio Parmiani and Antoni Ribas and Pedro Romero and Schreiber, {Robert D.} and Gerold Schuler and Srivastava, {Pramod K.} and Eric Tartour and Danila Valmori and {van der Burg}, {Sjoerd H.} and {van der Bruggen}, Pierre and {van den Eynde}, {Beno{\^i}t J.} and Ena Wang and Weiping Zou and Whiteside, {Theresa L.} and Speiser, {Daniel E.} and Pardoll, {Drew M.} and Restifo, {Nicholas P.} and Anderson, {Ana C.}",

note = "Publisher Copyright: {\textcopyright} 2015 Taylor & Francis Group, LLC.",

year = "2015",

doi = "10.1080/2162402X.2014.998538",

language = "English (US)",

volume = "4",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "4",

}

TY - JOUR

T1 - Consensus nomenclature for CD8+ T cell phenotypes in cancer

AU - Apetoh, Lionel

AU - Smyth, Mark J.

AU - Drake, Charles G.

AU - Abastado, Jean Pierre

AU - Apte, Ron N.

AU - Ayyoub, Maha

AU - Blay, Jean Yves

AU - Bonneville, Marc

AU - Butterfield, Lisa H.

AU - Caignard, Anne

AU - Castelli, Chiara

AU - Cavallo, Federica

AU - Celis, Esteban

AU - Chen, Lieping

AU - Colombo, Mario P.

AU - Comin-Anduix, Begoña

AU - Coukos, Georges

AU - Dhodapkar, Madhav V.

AU - Dranoff, Glenn

AU - Frazer, Ian H.

AU - Fridman, Wolf Hervé

AU - Gabrilovich, Dmitry I.

AU - Gilboa, Eli

AU - Gnjatic, Sacha

AU - Jäger, Dirk

AU - Kalinski, Pawel

AU - Kaufman, Howard L.

AU - Kiessling, Rolf

AU - Kirkwood, John

AU - Knuth, Alexander

AU - Liblau, Roland

AU - Lotze, Michael T.

AU - Lugli, Enrico

AU - Marincola, Francesco

AU - Melero, Ignacio

AU - Melief, Cornelis J.

AU - Mempel, Thorsten R.

AU - Mittendorf, Elizabeth A.

AU - Odun, Kunle

AU - Overwijk, Willem W.

AU - Palucka, Anna Karolina

AU - Parmiani, Giorgio

AU - Ribas, Antoni

AU - Romero, Pedro

AU - Schreiber, Robert D.

AU - Schuler, Gerold

AU - Srivastava, Pramod K.

AU - Tartour, Eric

AU - Valmori, Danila

AU - van der Burg, Sjoerd H.

AU - van der Bruggen, Pierre

AU - van den Eynde, Benoît J.

AU - Wang, Ena

AU - Zou, Weiping

AU - Whiteside, Theresa L.

AU - Speiser, Daniel E.

AU - Pardoll, Drew M.

AU - Restifo, Nicholas P.

AU - Anderson, Ana C.

PY - 2015

Y1 - 2015

N2 - Whereas preclinical investigations and clinical studies have established that CD8+ T cells can profoundly affect cancer progression, the underlying mechanisms are still elusive. Challenging the prevalent view that the beneficial effect of CD8+ T cells in cancer is solely attributable to their cytotoxic activity, several reports have indicated that the ability of CD8+T cells to promote tumor regression is dependent on their cytokine secretion profile and their ability to self-renew. Evidence has also shown that the tumor microenvironment can disarm CD8+ T cell immunity, leading to the emergence of dysfunctional CD8+ T cells. The existence of different types of CD8+ T cells in cancer calls for a more precise definition of the CD8+ T cell immune phenotypes in cancer and the abandonment of the generic terms “pro-tumor” and “antitumor.” Based on recent studies investigating the functions of CD8+ T cells in cancer, we here propose some guidelines to precisely define the functional states of CD8+T cells in cancer.

AB - Whereas preclinical investigations and clinical studies have established that CD8+ T cells can profoundly affect cancer progression, the underlying mechanisms are still elusive. Challenging the prevalent view that the beneficial effect of CD8+ T cells in cancer is solely attributable to their cytotoxic activity, several reports have indicated that the ability of CD8+T cells to promote tumor regression is dependent on their cytokine secretion profile and their ability to self-renew. Evidence has also shown that the tumor microenvironment can disarm CD8+ T cell immunity, leading to the emergence of dysfunctional CD8+ T cells. The existence of different types of CD8+ T cells in cancer calls for a more precise definition of the CD8+ T cell immune phenotypes in cancer and the abandonment of the generic terms “pro-tumor” and “antitumor.” Based on recent studies investigating the functions of CD8+ T cells in cancer, we here propose some guidelines to precisely define the functional states of CD8+T cells in cancer.

KW - Anergy

KW - Anticancer immunity

KW - CD8 T cells

KW - Cytotoxicity

KW - Effector

KW - Exhaustion

KW - IFNγ

KW - Senescence

KW - Stemness

UR - http://www.scopus.com/inward/record.url?scp=84954349779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954349779&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2014.998538

DO - 10.1080/2162402X.2014.998538

M3 - Article

AN - SCOPUS:84954349779

SN - 2162-4011

VL - 4

JO - OncoImmunology

JF - OncoImmunology

IS - 4

ER -